Movement Alert|Asymchem Laboratories Falls 5.05% in Regular Trading, Multiple Institutional Shareholders Reduce Holdings Amid Sector-Wide Weakness

Market Focus07-17

On July 17, Asymchem Laboratories (06821.HK) declined 5.05% in regular trading, trading at HK$119.0/share, with turnover of HK$39.71 million. The pullback follows the stock's sharp rally in prior sessions that triggered an abnormal trading alert.

On the news front, multiple institutional shareholders disclosed position reductions. On July 14, Schroders PLC and Norges Bank simultaneously sold a combined 510,300 shares worth approximately HK$64.88 million. Schroders reduced its stake to 13.41% while Norges Bank's holding fell to 7.40%. Separately, Schroders also sold 208,000 shares on July 15 at HK$132.76 per share, further lowering its position to 12.66%. JPMorgan also reduced 57,400 shares on July 9. The company's A-share had previously been flagged for abnormal trading after cumulative gains exceeded 20% over three consecutive trading days.

Within the Pharmaceuticals sector, the overall sector is broadly weaker. Among individual stocks, CSPC Pharma down 3.6%, SBP Group down 5.13%, Hansoh Pharma down 3.14%, Hengrui Pharma down 3.71%, Luye Pharma down 3.6%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment